Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

221. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials

Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised (...) controlled trials Fox B, Kahn S, Langleben D, Eisenberg M, Shimony A CRD summary This review concluded that novel oral anticoagulants had a similar risk of recurrence of acute venous thromboembolism and all-cause mortality when compared with vitamin K antagonists; rivaroxaban was associated with a reduced risk of bleeding. The authors acknowledged limitations in the evidence that mean the results of the review should be treated with caution. Authors' objectives To evaluate the effectiveness of the novel

DARE.2012

222. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review

Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review Adam SS, McDuffie JR, Ortel TL (...) , Williams JW CRD summary The authors concluded that new oral anticoagulants were effective for patients receiving long-term anticoagulation. The benefits compared with warfarin were small and varied depending on the control achieved with warfarin. This was generally a well-conducted review and the conclusions are likely to be reliable. Authors' objectives To compare the benefits and harms of new oral anticoagulants versus warfarin for patients with atrial fibrillation and venous thromboembolism

DARE.2012

223. Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-Term Prevention and Treatment of Arterial and Venous Thromboembolism

Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-Term Prevention and Treatment of Arterial and Venous Thromboembolism Management Briefs Search the HSR&D website Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs Health Services Research & Development Management Briefs Management Briefs: Provide VA senior managers with results from VA Health Services Research in a concise

Veterans Affairs - R&D2012

224. Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study

Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study 22939362 2012 10 26 2013 03 28 2013 04 29 1555-7162 125 11 2012 Nov The American journal of medicine Am. J. Med. Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. 1095-102 10.1016/j.amjmed.2012.04.005 S0002-9343(12)00287-2 Clinical scores may help physicians to better assess the individual risk/benefit of oral anticoagulant therapy (...) . We aimed to externally validate and compare the prognostic performance of 7 clinical prediction scores for major bleeding events during oral anticoagulation therapy. We followed 515 adult patients taking oral anticoagulants to measure the first major bleeding event over a 12-month follow-up period. The performance of each score to predict the risk of major bleeding and the physician's subjective assessment of bleeding risk were compared with the C statistic. The cumulative incidence of a first

EvidenceUpdates2012

225. Argatroban (Exembol) - anticoagulation in adult patients with heparin-induced thrombocytopenia type II

Argatroban (Exembol) - anticoagulation in adult patients with heparin-induced thrombocytopenia type II

Scottish Medicines Consortium2012

226. Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial

Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial 23033226 2012 10 03 2013 02 27 2013 11 21 1875-9114 32 10 2012 Oct Pharmacotherapy Pharmacotherapy Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial. 871-9 10.1002/j.1875-9114.2012.01116 To evaluate the impact of a pharmacist-led warfarin patient self-management program on quality (...) of life and anticoagulation control compared with management in a physician-led specialized anticoagulation clinic. Prospective, randomized, controlled, open-label trial. Tertiary care academic medical center. A total of 114 patients aged 18-75 years who were followed at a specialized anticoagulation clinic, had received warfarin for at least 6 months, and were expected to continue warfarin for a minimum of 4 months. All patients attended an educational session on anticoagulation provided by a pharmacist. Patients

EvidenceUpdates2012

227. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomised controlled trials

Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomised controlled trials Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomised controlled trials Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute (...) are consistent and support the authors conclusions. Authors' objectives To evaluate the efficacy and safety of new generation oral anticoagulant agents compared with placebo in patients receiving antiplatelet therapy after acute coronary syndrome (ACS). Searching PubMed, ClinicalTrials.gov and Scopus were searched without language restriction for studies published between 2000 and December 2011; search terms were reported. Reference lists of studies, reviews, editorials and letters and relevant conference

DARE.2012

228. Two monitoring methods of oral anticoagulant therapy in patients with mechanical heart valve prothesis: a meta-analysis

Two monitoring methods of oral anticoagulant therapy in patients with mechanical heart valve prothesis: a meta-analysis Two monitoring methods of oral anticoagulant therapy in patients with mechanical heart valve prothesis: a meta-analysis Two monitoring methods of oral anticoagulant therapy in patients with mechanical heart valve prothesis: a meta-analysis Xu Z, Wang Z, Ou J, Xu Y, Yang S, Zhang X CRD summary This generally well-conducted review concluded that self monitoring or self (...) management could improve the quality of oral anticoagulant therapy in patients with mechanical heart valve prostheses compared with traditional monitoring. Although the evidence base was limited, the authors' conclusions are likely to be reliable. Authors' objectives To compare the effectiveness of self monitoring or self management of oral anticoagulant therapy with conventional monitoring in patients with mechanical heart valve prostheses. Searching Eleven databases were searched (including MEDLINE

DARE.2012

229. Review: New oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF.

Review: New oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF. ACP Journal Club. Review: new oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography (...) Citation manager Format Create File 1 selected item: 22986394 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Sep 18;157(6):JC3-2. doi: 10.7326/0003-4819-157-6-201209180-02002. ACP Journal Club. Review: new oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF. . Comment on [Am J Cardiol. 2012

Annals of Internal Medicine2012

230. Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial

Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial 22700854 2012 07 17 2012 10 02 2015 11 19 1524-4539 126 3 2012 Jul 17 Circulation Circulation Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. 343-8 10.1161 (...) /CIRCULATIONAHA.111.090464 Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required. The current analysis was undertaken to compare the periprocedural bleeding risk of patients in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial treated with dabigatran and warfarin. Bleeding rates were evaluated from 7 days before until 30 days after invasive

EvidenceUpdates2012

232. Should Patients With Nephrotic Syndrome Receive Anticoagulation?

Should Patients With Nephrotic Syndrome Receive Anticoagulation? Should Patients With Nephrotic Syndrome Receive Anticoagulation? | Clinical Correlations Should Patients With Nephrotic Syndrome Receive Anticoagulation? May 9, 2012 By Jennifer Mulliken Faculty Peer Reviewed Case 1: A 30-year-old African-American male with a history of bilateral pulmonary emboli presents with a 1-week history of bilateral lower extremity edema. Blood pressure is 138/83, cholesterol 385, LDL 250, albumin 2.9 (...) . Urinalysis shows 3+ protein. Twenty-four hour urinary protein is 7.2 grams. Case 2: A 47-year-old Hispanic male with a history of mild hypertension and venous insufficiency presents with a 3-month history of bilateral lower extremity edema. BP is 146/95, cholesterol 241, LDL 165, albumin 1.9. Urinalysis shows 3+ protein. Twenty-four hour urinary protein is 4.6 grams. What is the evidence to support prophylactic anticoagulation in patients with nephrotic syndrome? Nephrotic syndrome classically presents

Clinical Correlations2012

233. Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies

Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies (...) Paciaroni M, Agnelli G, Venti M, Alberti A, Acciarresi M, Caso V CRD summary The review found that early treatment with anticoagulants was associated with a significant reduction in pulmonary embolism and a non-significant reduction in death, with the trade-off of a non-significant increase in haematoma enlargement in patients with acute haemorrhagic stroke. Due to limited evidence of variable quality, the conclusions should be considered tentative. Authors' objectives To assess the efficacy and safety

DARE.2012

234. The business case for quality improvement: oral anticoagulation for atrial fibrillation

The business case for quality improvement: oral anticoagulation for atrial fibrillation The business case for quality improvement: oral anticoagulation for atrial fibrillation The business case for quality improvement: oral anticoagulation for atrial fibrillation Rose AJ, Berlowitz DR, Ash AS, Ozonoff A, Hylek EM, Goldhaber-Fiebert JD Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to evaluate the cost-effectiveness of a quality improvement programme to improve blood coagulation control for patients with atrial fibrillation who were on anticoagulants to prevent stroke. The programme was likely to be cost-saving for the payer, even if it was only modestly effective and more expensive than similar programmes. Given

NHS Economic Evaluation Database.2012

235. Triple therapy rather than triple threat: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment

Triple therapy rather than triple threat: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment Triple therapy rather than triple threat: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment Triple therapy rather than triple threat: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving (...) long-term oral anticoagulant treatment Zhao HJ, Zheng ZT, Wang ZH, Li SH, Zhang Y, Zhong M, Zhang W CRD summary The authors concluded that triple antithrombotic therapy was superior to dual antiplatelet therapy in reducing cardiovascular events and mortality, although with a higher rate of major bleeding. Potential biases in the search and selection of studies and unclear details about study design and quality made the reliability of the conclusions unclear. Authors' objectives To evaluate

DARE.2012

236. New Oral Anticoagulants for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation

New Oral Anticoagulants for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation New Oral Anticoagulants for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation | CADTH.ca Find the information you need New Oral Anticoagulants for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation New Oral Anticoagulants for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation Published on: January 31, 2012 Project (...) Number: TR0002 Product Line: Therapeutic Review Result type: Report Warfarin has been the mainstay of oral anticoagulant therapy for many years. Now, new oral anticoagulants are being used to prevent stroke and other thromboembolic events in patients with atrial fibrillation. This project assessed the newer oral anticoagulants: dabigatran (Pradax), rivaroxaban (Xarelto), and apixaban (Eliquis). Related projects : An extension to this project, which will include antiplatelet drugs

CADTH - Therapeutic Review2012

237. Self monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data

Self monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data Self monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data Self monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data Heneghan C, Ward A, Perera R CRD summary This high-quality IPD review found that self monitoring reduced thromboembolic events without increasing major haemorrhages and death. The review (...) utilised appropriate methods to minimise potential biases and the conclusions are likely to be reliable. Authors' objectives To assess the effect of self-monitoring of oral anticoagulation on time to death, first major haemorrhage and first thromboembolic event, including the effect in important patient subgroups Searching EMBASE (1980 to 2009), MEDLINE (1966 to 2009), CINAHL (1982 to 2009), The Cochrane Library (issue 2, 2009) and Cochrane Central Register of Controlled Trials (CENTRAL) were searched

DARE.2012

238. New anticoagulants: a well-dosed introduction

New anticoagulants: a well-dosed introduction New anticoagulants: a well-dosed introduction New anticoagulants: a well-dosed introduction Health Council of the Netherlands Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Council of the Netherlands. New anticoagulants: a well-dosed introduction. The Hague: Health Council of the Netherlands Gezondheidsraad (...) (GR). 2012/07E. 2012 Authors' objectives Currently nearly 400,000 people in the Netherlands are being treated with anticoagulants of a type Vitamin K antagonists (VKAs). Although VKAs are very effective in treating and preventing thrombosis and embolisms, there are some important disadvantages to taking these 'blood thinners' on a daily basis. The primary objection is that treatment with VKAs requires intensive supervision and monitoring. VKAs also interact with a large number of foods and other

Health Technology Assessment (HTA) Database.2012

239. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Miller CS, Grandi SM, Shimony A, Filion (...) KB, Eisenberg MJ CRD summary The authors concluded that new oral anticoagulants were more efficacious than warfarin in prevention of stroke and systemic embolism in patients with atrial fibrillation, and have a more favourable safety profile. Possibility of missed unpublished studies, unclear levels of bias during review process and scarcity of trial quality information mean that the reliability of these conclusions is difficult to assess. Authors' objectives To compare the efficacy and safety

DARE.2012

240. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials

Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous (...) stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P CRD summary This review concluded that non-vitamin-K-antagonist oral anticoagulants seem to be associated with significant reductions in the rates of stroke or systemic embolism, haemorrhagic stroke, and major bleeding when compared with warfarin in patients with previous stroke or transient ischaemic attack. Given a number

DARE.2012